Biodesix Details Lung Nodule Growth Plan, Primary Care Push at TD Cowen Healthcare Conference [Yahoo! Finance]
Biodesix, Inc. (BDSX)
Company Research
Source: Yahoo! Finance
Biodesix is focused on the large, underserved lung nodule market with five Medicare-covered tests and estimates ~6 million new nodules annually; it's expanding into targeted primary care referral networks (about 15,000 PCPs that manage 80% of nodules) to access roughly 50% of the market. The company scaled its commercial team from about 65 to just under 100 reps while maintaining roughly $1 million revenue per rep , and sees 2026 upside from lung diagnostics (volume and ASPs) plus growth in biopharma services, supported by real-world evidence from the 4,000-patient Clarify study. Biodesix reported ~ 80% gross margins and achieved adjusted EBITDA positivity in Q4, is pursuing lab automation and other initiatives to drive margin and cash-flow improvement, and recently strengthened its balance sheet with a $14.7 million raise and debt refinancing. Interested in Biodesix, Inc.? Here are five stocks we like better. Biodesix (NASDAQ:BDSX) outlined its current commercial focus, grow
Show less
Read more
Impact Snapshot
Event Time:
BDSX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
BDSX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
BDSX alerts
High impacting Biodesix, Inc. news events
Weekly update
A roundup of the hottest topics
BDSX
News
- Are Medical Stocks Lagging Biodesix (BDSX) This Year? [Yahoo! Finance]Yahoo! Finance
- Biodesix (BDSX) was upgraded by William Blair from "market perform" to "outperform".MarketBeat
- Biodesix outlines $106M–$112M 2026 revenue target as sales expansion drives 41% Q4 growth [Seeking Alpha]Seeking Alpha
- Biodesix (BDSX) Q4 2025 Earnings Call Transcript [Yahoo! Finance]Yahoo! Finance
- Biodesix Q4 Earnings Call Highlights [Yahoo! Finance]Yahoo! Finance
BDSX
Earnings
- 2/26/26 - Beat
BDSX
Sec Filings
- 2/26/26 - Form 10-K
- 2/26/26 - Form 8-K
- 2/23/26 - Form 4
- BDSX's page on the SEC website